Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion
Status:
Not yet recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
Retinal vein occlusion (RVO) may lead to series of complications including retinal ischemia,
macular edema (ME) and induce vision impairment. Intravitreal injection of Ranibizumab
(0.5mg) has been proved to be a safe and effective method for the treatment of RVO-ME. In
this study, different treatment regimens of Ranibizumab is applied and the effects is
observed at 1-6 months to explore the best regimen for RVO. After 6 months, anti-VEGF therapy
and/or laser photocoagulation is used to explore whether laser photocoagulation can maintain
the therapeutic effect of Ranibizumab or reduce the injection number.